Oncometabolites drive tumorigenesis by enhancing protein acylation: from chromosomal remodelling to nonhistone modification

Y Fu, J Yu, F Li, S Ge - Journal of Experimental & Clinical Cancer …, 2022 - Springer
Metabolites are intermediate products of cellular metabolism catalysed by various enzymes.
Metabolic remodelling, as a biochemical fingerprint of cancer cells, causes abnormal …

Cell penetrating peptides: efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules

SM Farkhani, A Valizadeh, H Karami, S Mohammadi… - Peptides, 2014 - Elsevier
Efficient delivery of therapeutic and diagnostic molecules to the cells and tissues is a difficult
challenge. The cellular membrane is very effective in its role as a selectively permeable …

[HTML][HTML] On the design principles of peptide–drug conjugates for targeted drug delivery to the malignant tumor site

EI Vrettos, G Mező, AG Tzakos - Beilstein journal of organic …, 2018 - beilstein-journals.org
Cancer is the second leading cause of death affecting nearly one in two people, and the
appearance of new cases is projected to rise by> 70% by 2030. To effectively combat the …

Crossing epigenetic frontiers: the intersection of novel histone modifications and diseases

W Yao, X Hu, X Wang - Signal Transduction and Targeted Therapy, 2024 - nature.com
Histone post-translational modifications (HPTMs), as one of the core mechanisms of
epigenetic regulation, are garnering increasing attention due to their close association with …

Cell-penetrating peptides: Possible transduction mechanisms and therapeutic applications

Z Guo, H Peng, J Kang, D Sun - Biomedical reports, 2016 - spandidos-publications.com
Abstract Cell-penetrating peptides (CPPs), also known as protein transduction domains, are
a class of diverse peptides with 5‑30 amino acids. CPPs are divided into cationic …

Drug delivery and release systems for targeted tumor therapy

D Böhme, AG Beck‐Sickinger - Journal of Peptide Science, 2015 - Wiley Online Library
Most toxic agents currently used for chemotherapy show a narrow therapeutic window,
because of their inability to distinguish between healthy and cancer cells. Targeted drug …

Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates

DJ Worm, S Els‐Heindl, AG Beck‐Sickinger - Peptide Science, 2020 - Wiley Online Library
Specifically addressing cell surface molecules on cancer cells facilitates targeted cancer
therapies that offer the potential to selectively destroy malignant cells, while sparing healthy …

NGR-peptide− drug conjugates with dual targeting properties

KN Enyedi, S Tóth, G Szakács, G Mező - PLoS One, 2017 - journals.plos.org
Peptides containing the asparagine-glycine-arginine (NGR) motif are recognized by
CD13/aminopeptidase N (APN) receptor isoforms that are selectively overexpressed in …

Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies

P Limonta, M Manea - Cancer treatment reviews, 2013 - Elsevier
Prostate cancer is androgen-dependent in its early stages and androgen deprivation
therapy represents the most effective first-line therapeutic approach. However, after an initial …

Enhanced in vitro antitumor activity of GnRH-III-daunorubicin bioconjugates influenced by sequence modification

S Schuster, B Biri-Kovács, B Szeder, L Buday, J Gardi… - Pharmaceutics, 2018 - mdpi.com
Receptors for gonadotropin releasing hormone (GnRH) are highly expressed in various
human cancers including breast, ovarian, endometrial, prostate and colorectal cancer …